Our efficacy trained methods are applicable to any drug target, but as highlighted in our invited submission to Nature Biopharmaceutical Dealmakers (featured in Nature Reviews Drug Discovery and Nature Biotechnology), Azor was founded to design small molecules able to target microRNA and monitor their efficacy.
The current market for RNA-targeted small molecules is valued over $113-billion, with only four established drug targets. Azor Biotek's innovative approach allows for the design of novel molecules to target any RNA — opening many previously inaccessible avenues for therapeutic development as every disease has multiple unexploited RNA drug targets .
microRNA
microRNA (miR) are massively multimodal transcript regulators, facilitating profound treatment responses. For instance, miR-29 silence 99-oncogenes simultaneously, making it the most effective natural tumour suppressor. miR-targeted therapeutic design is our specially.
RNA Target Selection
All RNA is targetable — though not always directly, selectively or safely.
Our philosophy of what constitutes the targetable transcriptome
We employ an AI-guided systems biology target selection process, with target interactome analysis to score a candidate RNA drug target for intrinsic safety, targetability, conservation, distribution and efficacy. This methodology successfully identifies the safety outcomes of existent RNA target clinical trials. Low cost project feasibility services for target identification are available for any given disease indication.
Virtual Screens
Best-in class for RNA/protein interfaces, guided by the latest molecular dynamic parameters alongside novel gridscoring and solvation methods.